Down 16.9% in 4 Weeks, Here's Why Conmed ( CNMD ) Looks Ripe for a Turnaround
The heavy selling pressure might have exhausted for Conmed (CNMD) as it is technically in oversold territory now. In addition to this technical measure, strong agreement among Wall Street analysts in revising earnings estimates higher indicates that the stock is ripe for a trend reversal.
Is CONMED ( CNMD ) Stock Undervalued Right Now?
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.
Conmed ( CNMD ) is a Top-Ranked Growth Stock: Should You Buy?
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
Wall Street Analysts Think Conmed ( CNMD ) Could Surge 25.54%: Read This Before Placing a Bet
The average of price targets set by Wall Street analysts indicates a potential upside of 25.5% in Conmed (CNMD). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.
Here's Why Conmed ( CNMD ) is a Strong Momentum Stock
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
CNMD or MMSI: Which Is the Better Value Stock Right Now?
CNMD vs. MMSI: Which Stock Is the Better Value Option?
Should Value Investors Buy Cardinal Health ( CAH ) Stock?
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.
Are You a Value Investor? This 1 Stock Could Be the Perfect Pick
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
CONMED Q3 Earnings and Revenues Beat Estimates, Margins Contract
CNMD beats third-quarter 2025 estimates on strength in surgery segments, but gross and operating margins see sharp contraction.
Conmed ( CNMD ) Tops Q3 Earnings and Revenue Estimates
Conmed (CNMD) delivered earnings and revenue surprises of +2.86% and +0.42%, respectively, for the quarter ended September 2025. Do the numbers hold clues to what lies ahead for the stock?
Henry Schein ( HSIC ) Q3 Earnings and Revenues Beat Estimates
Henry Schein (HSIC) delivered earnings and revenue surprises of +8.66% and +2.02%, respectively, for the quarter ended September 2025. Do the numbers hold clues to what lies ahead for the stock?
Can Sustained Product Demand Drive BDX Stock Before Q4 Earnings?
BD rides high on product demand across segments, but fourth-quarter fiscal 2025 results may face pressure from global market dynamics.
Align Technology ( ALGN ) Q3 Earnings and Revenues Surpass Estimates
Align Technology (ALGN) delivered earnings and revenue surprises of +10.13% and +2.49%, respectively, for the quarter ended September 2025. Do the numbers hold clues to what lies ahead for the stock?
ISRG Bets on SP Platform to Capture Rising ASC Procedure Volume
Intuitive Surgical's SP platform is gaining traction as a cost-efficient, high-throughput option for ASCs, complementing da Vinci 5 in hospitals.
Why Conmed ( CNMD ) is a Top Growth Stock for the Long-Term
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
Here's Why Conmed ( CNMD ) is a Strong Value Stock
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
Are You a Growth Investor? This 1 Stock Could Be the Perfect Pick
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
Here's Why Conmed ( CNMD ) is a Strong Momentum Stock
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
Here's Why You Should Retain CONMED Stock in Your Portfolio for Now
CNMD's growth drivers - AirSeal, Buffalo Filter, BioBrace, and Foot & Ankle - are offsetting tariffs and supply risks, making the stock worth retaining.
Why Conmed ( CNMD ) is a Top Value Stock for the Long-Term
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
Here's Why Conmed ( CNMD ) is a Strong Growth Stock
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
Why Conmed ( CNMD ) is a Top Momentum Stock for the Long-Term
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
Are You a Value Investor? This 1 Stock Could Be the Perfect Pick
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
Why Conmed ( CNMD ) is a Top Growth Stock for the Long-Term
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
Conmed ( CNMD ) Q2 EPS Jumps 17%
Conmed ( NYSE:CNMD ) , a medical technology company specializing in surgical devices, reported its financial results on July 30, 2025. The headline news from the release was that both GAAP revenue and adjusted earnings per share ( non-GAAP ) topped analyst projections, with GAAP revenue reaching ...
CONMED Q2 Earnings & Revenues Beat Estimates, 2025 Outlook Raised
CNMD reports solid second-quarter results, driven by improving sales across both segments.
Conmed ( CNMD ) Q2 Earnings and Revenues Top Estimates
Conmed (CNMD) delivered earnings and revenue surprises of +1.77% and +0.81%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?
Here's Why You Should Retain CONMED Stock in Your Portfolio for Now
CNMD stock rides high on strong recurring revenues, margin gains, and surgical product growth despite supply and cybersecurity challenges.
Why Is Merit Medical Stock Trading Higher On Tuesday? - Merit Medical Systems ( NASDAQ:MMSI )
Q2 revenue expected to exceed analyst estimates with up to 14% growth. Analyst reaffirms Buy rating, sets $108 price forecast for MMSI. Up Next: Get 5 Dark Horse Stocks Wall Street Is Quietly Loading Up On Merit Medical Systems Inc.
Merit Medical Names Martha Aronson as New President and Chief Executive Officer - Merit Medical Systems ( NASDAQ:MMSI )
Fred Lampropoulos will continue to serve as Chairman of Merit's Board of Directors Merit announces preliminary unaudited revenue for the quarter ended June 30, 2025 SOUTH JORDAN, Utah, July 07, 2025 ( GLOBE NEWSWIRE ) -- Merit Medical Systems, Inc.
This Conagra Brands Analyst Turns Bearish; Here Are Top 3 Downgrades For Thursday - Anglogold Ashanti ( NYSE:AU ) , Conagra Brands ( NYSE:CAG )
Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades, downgrades and initiations, please see our analyst ratings page.
Here's Why You Should Retain CONMED Stock in Your Portfolio for Now
CNMD stock rides high on strong recurring revenues, margin gains, and surgical product growth despite supply and cybersecurity challenges.
CVS Health Posts Better-Than-Expected Earnings, Joins CommScope, Microsoft, Meta, Chart Industries, And Other Big Stocks Moving Higher On Thursday - Advanced Energy Indus ( NASDAQ:AEIS ) , ATI ( NYSE:ATI )
U.S. stocks were higher, with the Dow Jones index gaining around 400 points on Thursday. Shares of CVS Health Corporation CVS rose sharply during Thursday's session after the company reported better-than-expected first-quarter results and raised FY25 EPS guidance.
CNMD Stock Up On Q1 Earnings & Sales Beat, Raised 2025 Outlook
CNMD reports solid first-quarter results, driven by improving sales across both segments.
Conmed ( CNMD ) Surpasses Q1 Earnings and Revenue Estimates
Conmed (CNMD) delivered earnings and revenue surprises of 17.28% and 2.42%, respectively, for the quarter ended March 2025. Do the numbers hold clues to what lies ahead for the stock?
4 Stocks to Watch as Dental Supplies Recovers Amid Tariff Headwind
Here we discuss four stocks from the Dental Supplies industry that are likely to earn wealth for investors. These are CAH, MMSI, XRAY and CNMD.
Here's Why You Should Retain CONMED Stock in Your Portfolio for Now
CNMD is poised for growth on the back of strong product offerings and recurring revenues but faces headwinds from regulatory challenges, supply-chain constraints and cybersecurity risks.
Global Bariatric Surgeries Market to Hit USD 27.64 Billion by 2030, Fueled by Rising Demand for Minimally Invasive Techniques - The Insight Partners
US & Canada, April 01, 2025 ( GLOBE NEWSWIRE ) -- US & Canada, Mar, 21, 2025 ( GlobeNewswire ) -- According to a comprehensive report from The Insight Partners, "Bariatric Surgeries Market Size and Forecast ( 2020 - 2030 ) , Global and Regional Share, Trend, and Growth Opportunity Analysis ...
Conmed ( CNMD ) Down 12.2% Since Last Earnings Report: Can It Rebound?
Conmed (CNMD) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Conmed ( CNMD ) Down 12.2% Since Last Earnings Report: Can It Rebound?
Conmed (CNMD) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
New Strong Sell Stocks for February 19th
ACDVF, BN and CNMD have been added to the Zacks Rank #5 (Strong Sell) List on February 19, 2024.
New Strong Sell Stocks for February 11th
ATS, CNMD and CSX have been added to the Zacks Rank #5 (Strong Sell) List on February 11, 2025.
CNMD's Q4 Earnings & Sales Beat Estimates, Stock Down on Weak Outlook
CONMED reports solid fourth-quarter results, fueled by strength in the General Surgery segment and continued demand for AirSeal product.
This Match Group Analyst Is No Longer Bullish; Here Are Top 5 Downgrades For Thursday - FormFactor ( NASDAQ:FORM ) , Conmed ( NYSE:CNMD )
Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades, downgrades and initiations, please see our analyst ratings page. Evercore ISI Group analyst Shweta Khajuria downgraded the rating for Match Group, Inc.
These Analysts Slash Their Forecasts On Conmed After Q4 Results - Conmed ( NYSE:CNMD )
CONMED Corporation CNMD posted better-than-expected earnings for its fourth quarter, but issued FY25 earnings and revenue guidance below estimates. Conmed reported quarterly earnings of $1.34 per share which beat the analyst consensus estimate of $1.20 per share.
Conmed ( CNMD ) Surpasses Q4 Earnings and Revenue Estimates
Conmed (CNMD) delivered earnings and revenue surprises of 11.67% and 1.36%, respectively, for the quarter ended December 2024. Do the numbers hold clues to what lies ahead for the stock?
Cardinal Health ( CAH ) Surpasses Q2 Earnings and Revenue Estimates
Cardinal (CAH) delivered earnings and revenue surprises of 10.29% and 0.69%, respectively, for the quarter ended December 2024. Do the numbers hold clues to what lies ahead for the stock?
Conmed ( CNMD ) Earnings Expected to Grow: Should You Buy?
Conmed (CNMD) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Should Value Investors Buy CONMED ( CNMD ) Stock?
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.
Pro-Dex Stock Skyrockets Over the Past Year: A Must Buy?
Investors can consider investing in PDEX right now as the stock has done extremely well through 2024 and its prospects continue to shine.
